IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0042/2015, INT0043/2015, and INT0044/2016 The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone514-331-7440
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.82 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableNot Optionable
IntelGenx Technologies (OTCMKTS:IGXT) Frequently Asked Questions
What is IntelGenx Technologies' stock symbol?
IntelGenx Technologies trades on the OTCMKTS under the ticker symbol "IGXT."
How were IntelGenx Technologies' earnings last quarter?
IntelGenx Technologies Corp. (OTCMKTS:IGXT) posted its earnings results on Friday, March, 22nd. The company reported ($0.03) EPS for the quarter. The company earned $0.65 million during the quarter, compared to the consensus estimate of $0.20 million. IntelGenx Technologies had a negative return on equity of 288.24% and a negative net margin of 554.47%. View IntelGenx Technologies' Earnings History.
When is IntelGenx Technologies' next earnings date?
What price target have analysts set for IGXT?
2 equities research analysts have issued 12-month price targets for IntelGenx Technologies' stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate IntelGenx Technologies' stock price to reach $2.00 in the next year. This suggests a possible upside of 271.2% from the stock's current price. View Analyst Price Targets for IntelGenx Technologies.
What is the consensus analysts' recommendation for IntelGenx Technologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelGenx Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IntelGenx Technologies.
What are Wall Street analysts saying about IntelGenx Technologies stock?
Here are some recent quotes from research analysts about IntelGenx Technologies stock:
- 1. HC Wainwright analysts commented, "We maintain our Buy rating of IGXT and maintain our 12-month price target of $1.50 per diluted share. We derive our price target based on the average of two valuation methods: 1) price-earnings multiple using 25x 2025 EPS estimate discounted at 15%; and 2) discounted cash flow analysis using a 2% terminal growth rate and discounting 2025 free cash flow estimate at a 15% discount rate. (1) partnership; (2) manufacturing; (3) commercial; (4) financial; and (5) intellectual property." (3/26/2019)
- 2. According to Zacks Investment Research, "IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation. " (1/10/2019)
- 3. Maxim Group analysts commented, "IntelGenX reported 3Q18 revenue of $700K and a net loss of ($2.9M). The company ended the period with $2.2M in cash, excluding $12M raised in October in an equity offering. With current operating expenses of $3.3M, we estimate runway into late 2019." (11/9/2018)
Has IntelGenx Technologies been receiving favorable news coverage?
Headlines about IGXT stock have been trending positive on Tuesday, according to InfoTrie. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. IntelGenx Technologies earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
Who are some of IntelGenx Technologies' key competitors?
Some companies that are related to IntelGenx Technologies include Axovant Sciences (AXGT), Synlogic (SYBX), Acer Therapeutics (ACER), Mersana Therapeutics (MRSN), Tocagen (TOCA), VBI Vaccines (VBIV), Galectin Therapeutics (GALT), TAIWAN LIPOSOME/S (TLC), Recro Pharma (REPH), Nature's Sunshine Products (NATR), Galmed Pharmaceuticals (GLMD), Paratek Pharmaceuticals (PRTK), REDHILL BIOPHAR/S (RDHL), Adamas Pharmaceuticals (ADMS) and Syndax Pharmaceuticals (SNDX).
What other stocks do shareholders of IntelGenx Technologies own?
Who are IntelGenx Technologies' key executives?
IntelGenx Technologies' management team includes the folowing people:
- Dr. Horst G. Zerbe, Founder, Chairman, CEO, Pres & Chairman of Scientific Advisory Board (Age 72)
- Mr. Andre Godin CPA, CA, Exec. VP & CFO (Age 55)
- Dr. Dana Matzen, VP of Bus. & Corp. Devel. (Age 41)
- Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D (Age 42)
- Ms. Ingrid Zerbe, Co-Founder & Corp. Sec. (Age 65)
How do I buy shares of IntelGenx Technologies?
Shares of IGXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IntelGenx Technologies' stock price today?
One share of IGXT stock can currently be purchased for approximately $0.5388.
How big of a company is IntelGenx Technologies?
IntelGenx Technologies has a market capitalization of $50.39 million and generates $1.82 million in revenue each year. The company earns $-10,110,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.
What is IntelGenx Technologies' official website?
How can I contact IntelGenx Technologies?
IntelGenx Technologies' mailing address is 6420 ABRAMS, VILLE SAINT LAURENT A8, H4S 1Y2. The company can be reached via phone at 514-331-7440 or via email at [email protected]
MarketBeat Community Rating for IntelGenx Technologies (OTCMKTS IGXT)
MarketBeat's community ratings are surveys of what our community members think about IntelGenx Technologies and other stocks. Vote "Outperform" if you believe IGXT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IGXT will underperform the S&P 500 over the long term. You may vote once every thirty days.
